Le diagnostique du cancer du poumon à l’aide d’images 3D à haute résolution est particulièrement efficace pour détecter les phases précoces de la maladie mais engendre encore trop de faux positifs.  Le Deep Learning peut aider à limiter cela en analysant un grand nombres d’images et en alimentant les algorithmes de détections avec des analyses validées. Pour améliorer ces algorithmes, les entreprises Kaggle et Booz Allen Hamilton ont fait de ce sujet l’objectif du Data Science Bowl de cette année.

Les résultats de cette compétition ont été très encourageants (voir l’article) et nous montrent encore une fois que l’utilisation d’une assistance numérique à la catégorisation et à l’interprétation des images en biologie n’est pas une option, mais une obligation dans les années qui viennent.

Depuis janvier, près de 10 000 data scientists du monde entier ont participé à l’Annual Data Science Bowl. Pour cette troisième édition, le challenge des analystes consistait à développer les meilleurs algorithmes d’apprentissage machine permettant d’aider les professionnels de santé à dépister plus tôt et plus précisément les cancers du poumon lors des examens tomodensitométriques.

Source: LeMondeInformatique

If you don’t know what precision medicine is, you should read this clear article of Dr. Bertalan Mesko from the Medical Futurist℠ website.

Precision medicine is a new step in healthcare, because up to now drugs have been created as a global solution for a disease. It’s a good choice for “simple” (or mono factor) illnesses but much more inefficient for multiparametric ones like cancer or neurodegenerative diseases.

Currently, we know that everyone has a different genetic code, may react differently to pharmaceutics or may have a completely opposite reaction to treatment as assumed. So why should we treat everyone with the same drugs or with the same method?

In HCS Pharma, We strongly believe that phenotypic screening can be an help to implement precision medecine and that is the future in addition to do the systematic genotyping.

Thus, I truly believe that precision medicine is not a hype or an empty promise, but it is the only viable future for healthcare if we want to fight against cancer successfully.

Source: Precision Medicine Is Our Best Hope In The Fight Against Cancer – The Medical Futurist

The genetic mutations driving the apparition of tumors are commonly linked to environmental and intrinsic factors. The part of environmental risk versus mistakes in DNA replication have been heavily discuted through the year. In 2015, a publication by Vogelstein and Thomasetti bring a new theory explaining why some cancers occur more than others (Tomasetti and Vogelstein, 2015). Using statistical analysis of cancer cases in the U.S., they concluded that differences in the number of stem cell divisions in an organ are strongly correlated (0.81) with the total number of divisions of stem cells maintaining that tissue’s homeostasis with the frequency of cancers in that area. There aren’t as many stem cells in the brain, where few cancers occurred, than in the colon and intestine where occurred a lot of colorectal cancer. As this study is very controversial, hundred of studies have been written in response, bringing this topic update. Last paper of Vogelstein and Thomasetti conclude that the role of DNA typos is organ related, and indicated that about 66% of cancer-driving mutations are due to random DNA replication errors, with only 29% due to environmental factors and 5% to inherited mutations (Tomasetti et al., 2017).

Bibliography

 

If you want to increase your knowledge on DYRK1A (‘dual specificity, tyrosine phosphorylation regulated kinase 1A’), you have to be in Saint Malo at the end of march for the first “Dyrk conference”. We will be happy to participate to this scientific event !

DYRK1A (‘dual specificity, tyrosine phosphorylation regulated kinase 1A’) is a kinases which phosphorylates many substrates involved in signaling pathways. Kinase of the DIRK family play key roles in mRNA splicing, gene transcription, cell survival, differentiation, endocytosis, neuronal development and functions.

Abnormal activities of DIRK lead to several diseases, such as cognitive disorders observed in Down syndrome, Mental Retardation Disease 7 (MRD7) and Alzheimer’s disease. “High content screening” and “high content analysis” are a part of the development of potent and selective pharmacological inhibitors of DIRKs in order to characterize the therapeutic potential of DIRKs diseases treatments. You want to know more ? See our services and contact us, we will be very happy to share with you !

 

Quantifying DNA damage is mandatory to assess potential adverse effects of candidate drugs or molecules or extracts developed in the dermo-cosmetic industry, but also to assess the efficacy of therapeutic approaches with the aim of producing tumor cell genotoxicity in cancer treatment.

The comet assay is a sensitive, well established technique for quantifying DNA damage in eukaryotic cells. Compatible with the detection of a wide range of DNA damaging agents, its principle consists in the migration of fragmented DNA in an electrophoresis gel (damaged DNA forming the tail of the comet), while intact DNA moves at a slower rate (head of the comet). The percentage of fragmented DNA in the comet tail is a direct measure of DNA damage.

View and download on Slideshare (low quality) :
http://fr.slideshare.net/hcspharma/development-of-an-automated-comet-assay-for-genotoxicity-assessment-on-tk6-cell-line

Ask for high quality link by putting your email below

by multiplexing assays on have many advantages to find more efficient new drugs for treatment. Progress in the IT part, on softwares, on the uses on big data and in the machine on speed and sensitivity allow to do multiplexing assays in HCS . This article shows us another example on this multiplexing assays on tumour and .

The high-throughput assay procedures use ready-made plates, open-source software and are compatible with standard plate readers, therefore offering high predictive power with substantial savings in time and money.

Curated from www.plosone.org

“A new high-content screening software platform enables cancer researchers to uncover more about basic and advanced cellular function to accelerate cell-based research. The Thermo Scientific HCS Studio 2.0 is a high-content quantitative imaging and analysis software platform for a range of cancer research applications, including angiogenesis and migration/invasion, as well as the development of three-dimensional models of cancer stem cells and spheroid tumors. “

To know more on this information, follow this link!

Non-invasive cancer- diagnosis: a new application for HCS

HCS was first used in pharmaceutical industry to develop a new way to find new drugs. But this technology is extended since few years in other domains, as diagnosis!

source: http://www.int.laborundmore.de/news/694729/A-new-application-for-microscopy.html

Using automated high content screening and sophisticated computational modeling, the researchers’ screening and analysis of tens of millions of genetically manipulated cells helped them identify more than a dozen genes that influence cell shape. To go more in details of this article, follow this link.

%d bloggers like this: